Breast Cancer | Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer
Breast Cancer research study
What is the primary objective of this study?
This is a study to determine the prevalence and severity of alopecia (hair loss) experienced by postmenopausal breast cancer patients receiving endocrine therapy including Tamoxifen, Letrozole (Femara), Exemestane (Aromasin), or Anastrozole (Arimidex).
Who is eligible to participate?
Inclusion Criteria: - Postmenopausal women - Diagnosed with hormone-receptor positive breast cancer - Commenced adjuvant endocrine therapy ≥ 3 months ago, specifically Tamoxifen, Anastrozole, Exemestane, and/or Letrozole - Good command of the English language - Under the care of a medical oncologist at Princess Margaret Hospital Exclusion Criteria: - Previously received chemotherapy - Recurrent and/or metastatic disease - History of endocrine, dermatology, or immune system disorders known to alter hair growth (ie. Hypothyroidism and iron deficiency)
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Postmenopausal Women on Endocrine TherapyPostmenopausal women with Breast Cancer that undergo Endocrine Therapy.
Start Date: January 2011
Completed Date: January 2012
Primary Outcome: Severity of Alopecia Tool (SALT)
Secondary Outcome: Comparison of Tamoxifen, AI or Tamoxifen plus AI
Study sponsors, principal investigator, and references
Principal Investigator: Lindsay Carlsson
Lead Sponsor: University Health Network, Toronto